Aulos Bioscience Appoints Leo Redmond as Chief Financial Officer
News provided by
Share this article
Share this article
LARKSPUR, Calif., May 17, 2021 /PRNewswire/ Aulos Bioscience, a biotechnology company developing highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies as therapeutics against solid tumors, announced today that Leo Redmond will join the company as chief financial officer. Redmond brings to Aulos nearly three decades of financial experience in the biopharmaceutical industry. He will be based in the company s new headquarters in Larkspur, California. We are pleased to welcome Leo to Aulos at a time when we are rapidly building out our operations in California, preparing to start our first human trial of AU-007, planning our next fundraising scenarios, and defining the corporate strategy. Leo is a wonderful addition to our leadership team. His knowledge and expertise in leading all aspects of financial management for both private and public bi
California
United-states
Anderson-school
Cleo-redmond
Aron-knickerbocker
University-of-kansas
Genentech
Presidio-pharmaceuticals
Aulos-bioscience-inc
Genentech-foundation-for-biomedical-sciences
Anderson-school-of-management
Genentech-foundation